keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29352574/mismatch-repair-status-as-a-beneficial-predictor-of-fluorouracil-based-adjuvant-chemotherapy-for-pancreatic-cancer
#1
Dingkong Liang, Si Shi, Chen Liang, Qingcai Meng, Bo Zhang, Quanxing Ni, Jin Xu, Xianjun Yu
BACKGROUND: Prior studies have indicated that patients with colorectal cancer with deficient mismatch repair have particular clinicopathologic features that distinguish them from patients with tumors with proficient mismatch repair. However, the effect of the mismatch repair status on outcomes after adjuvant chemotherapy for pancreatic cancer is still unknown. METHODS: Pancreatic cancer patients who underwent R0 resection between January 2013 and December 2015 at Fudan University Shanghai Cancer Center were included in this study...
January 15, 2018: Surgery
https://www.readbyqxmd.com/read/29352327/limk-cofilin-pathway-and-slingshot-are-implicated-in-human-colorectal-cancer-progression-and-chemoresistance
#2
Helen Aggelou, Panagiota Chadla, Sofia Nikou, Sofia Karteri, Ioannis Maroulis, Haralabos P Kalofonos, Helen Papadaki, Vasiliki Bravou
Cofilin phospho-regulation is important for actin filament turnover and is implicated in cancer. Phosphorylation of cofilin is mediated by LIM kinases (LIMKs) and dephosphorylation by Slingshot phosphatases (SSH). LIMKs and SSH promote cancer cell invasion and metastasis and represent novel anti-cancer targets. However, little is known regarding LIMK/cofilin and SSH in human colorectal cancer (CRC). In this study, we aimed to address their expression and significance in human CRC. We evaluated expression of non-phosphorylated (active) and phosphorylated cofilin, LIMK1, LIMK2, and SSH1 by immunohistochemistry in 143 human CRC samples in relation to clinicopathologic parameters, response of metastatic disease to chemotherapy, and epithelial-mesenchymal transition (EMT) markers β-catenin, E-cadherin, and ZEB...
January 19, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29348854/acid-ceramidase-and-its-inhibitors-a-de-novo-drug-target-and-a-new-class-of-drugs-for-killing-glioblastoma-cancer-stem-cells-with-high-efficiency
#3
Ninh B Doan, Hisham Alhajala, Mona M Al-Gizawiy, Wade M Mueller, Scott D Rand, Jennifer M Connelly, Elizabeth J Cochran, Christopher R Chitambar, Paul Clark, John Kuo, Kathleen M Schmainda, Shama P Mirza
Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are more aggressive. Therapeutically resistant glioblastoma or glioblastoma stem-like cells (GSCs) are hypothesized to cause this inevitable recurrence. Identifying prognostic biomarkers of glioblastoma will potentially advance knowledge about glioblastoma tumorigenesis and enable discovery of more effective therapies...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29348387/cancer-stem-cells-and-molecular-biology-test-in-colorectal-cancer-therapeutic-implications
#4
Rustam Effendi-Ys
Colorectal cancer (CRC) is the third most frequent cancer in males, the second in females, and is the second leading cause of cancer related death worldwide. Within Indonesia's 250 million population, the incidence rates for CRC per 100,000 population were 15.2 for males and 10.2 for females, and estimated 63,500 cases per year.  More than 50% of colorectal cancer patients will develop metastasis. CRC is still the main cause of tumor-related death, and although most CRC patients are treated with surgery to remove the tumor tissue, some of the CRC patients recurred...
October 2017: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/29346573/the-addition-of-bevacizumab-to-oxaliplatin-based-chemotherapy-impact-upon-hepatic-sinusoidal-injury-and-thrombocytopenia
#5
Michael J Overman, Renata Ferrarotto, Kanwal Raghav, Binsah George, Wei Qiao, Karime K Machado, Leonard B Saltz, Thibault Mazard, J N Vauthey, Paulo M Hoff, Brian Hobbs, Evelyn M Loyer, Scott Kopetz
Background: Oxaliplatin-based chemotherapy can cause hepatic sinusoidal injury (HSI), portal hypertension, and splenic sequestration of platelets. Evidence suggests that bevacizumab may protect against HSI. Methods: Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)...
January 15, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29346040/bevacizumab-maintenance-versus-no-maintenance-during-chemotherapy-free-intervals-in-metastatic-colorectal-cancer-a-randomized-phase-iii-trial-prodige-9
#6
Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, Karine Le Malicot, Julien Taieb, Olivier Bouché, Jean-Marc Phelip, Eric François, Christian Borel, Roger Faroux, Laetitia Dahan, Stéphane Jacquot, Dominique Genet, Faiza Khemissa, Etienne Suc, Françoise Desseigne, Patrick Texereau, Come Lepage, Jaafar Bennouna
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer after induction chemotherapy. Patients and Methods In this open-label, phase III, randomized controlled trial, we compared the tumor control duration (TCD) observed with bevacizumab maintenance and with no treatment (observation) during CFI subsequent to induction chemotherapy with 12 cycles of fluorouracil, leucovorin, and irinotecan plus bevacizumab. After disease progression, the induction regimen was repeated for eight cycles, followed by a new CFI...
January 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29344244/identification-and-validation-of-psat1-as-a-potential-prognostic-factor-for-predicting-clinical-outcomes-in-patients-with-colorectal-carcinoma
#7
Cheng Qian, Yongsheng Xia, Yun Ren, Yan Yin, Anmei Deng
The aim of the present study was to explore the existence of known or candidate drug-target genes that are upregulated in colorectal cancer (CRC) and may serve as novel prognostic factors or therapeutic targets for this type of malignancy. An in silico analysis was conducted using the Oncomine tool to compare the expression levels of a list of drug-target genes between cancerous and normal tissues in 6 independent CRC cohorts retrieved from the Oncomine database. Phosphoserine aminotransferase 1 (PSAT1) was identified as the top-ranked upregulated gene in CRC tumors, and was highly expressed in patients with chemoresistant disease...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29343971/assessment-of-the-cardiac-safety-between-cetuximab-and-panitumumab-as-single-therapy-in-chinese-chemotherapy-refractory-mcrc
#8
Xue-Miao Tang, Hao Chen, Qing Li, Yiling Song, Shuping Zhang, Xiao-Shuan Xu, Yiwei Xu, Shulin Chen
Objective: The cardiac safety of cetuximab and panitumumab, particularly as single agents, has not been investigated extensively. This trial was designed to specifically evaluate the cardiac safety of cetuximab and panitumumab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer (mCRC) patients. Patients and methods: Sixty-one patients received cetuximab at an initial dose of 400 mg/m2 intravenously over 120 minutes on day 1 (week 1), followed by a maintenance dose of 250 mg/m2 intravenously over 60 minutes on day 1 of each 7-day cycle...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29343849/mutant-p53-gain-of-function-underlies-high-expression-levels-of-colorectal-cancer-stem-cells-markers
#9
Hilla Solomon, Nathan Dinowitz, Ioannis S Pateras, Tomer Cooks, Yoav Shetzer, Alina Molchadsky, Meital Charni, Stav Rabani, Gabriela Koifman, Ohad Tarcic, Ziv Porat, Ira Kogan-Sakin, Naomi Goldfinger, Moshe Oren, Curtis C Harris, Vassilis G Gorgoulis, Varda Rotter
Emerging notion in carcinogenesis ascribes tumor initiation and aggressiveness to cancer stem cells (CSCs). Specifically, colorectal cancer (CRC) development was shown to be compatible with CSCs hypothesis. Mutations in p53 are highly frequent in CRC, and are known to facilitate tumor development and aggressiveness. Yet, the link between mutant p53 and colorectal CSCs is not well-established. In the present study, we set to examine whether oncogenic mutant p53 proteins may augment colorectal CSCs phenotype...
January 18, 2018: Oncogene
https://www.readbyqxmd.com/read/29343143/colorectal-cancer-patients-preferences-for-type-of-caregiver-during-survivorship-care
#10
T Wieldraaijer, L A M Duineveld, S C Donkervoort, W B Busschers, H C P M van Weert, J Wind
PURPOSE: Colorectal cancer (CRC) survivors are currently included in a secondary care-led survivorship care programme. Efforts are underway to transfer this survivorship care to primary care, but met with some reluctance by patients and caregivers. This study assesses (1) what caregiver patients prefer to contact for symptoms during survivorship care, (2) what patient factors are associated with a preferred caregiver, and (3) whether the type of symptom is associated with a preferred caregiver...
January 17, 2018: Scandinavian Journal of Primary Health Care
https://www.readbyqxmd.com/read/29342159/prediction-of-novel-target-genes-and-pathways-involved-in-bevacizumab-resistant-colorectal-cancer
#11
Precious Takondwa Makondi, Chia-Hwa Lee, Chien-Yu Huang, Chi-Ming Chu, Yu-Jia Chang, Po-Li Wei
Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the therapeutic efficacy of bevacizumab. The Gene Expression Omnibus (GEO) database (dataset, GSE86525) was used to identify the key genes and pathways involved in bevacizumab-resistant mCRC. The GEO2R web tool was used to identify differentially expressed genes (DEGs)...
2018: PloS One
https://www.readbyqxmd.com/read/29341165/histopathological-and-molecular-classification-of-colorectal-cancer-and-corresponding-peritoneal-metastases
#12
I Ubink, W J van Eden, P Snaebjornsson, N F M Kok, J van Kuik, W M U van Grevenstein, M M Laclé, J Sanders, R J A Fijneman, S G Elias, I H M Borel Rinkes, A G J Aalbers, O Kranenburg
BACKGROUND: Patients with colorectal peritoneal carcinomatosis have a very poor prognosis. The recently developed consensus molecular subtype (CMS) classification of primary colorectal cancer categorizes tumours into four robust subtypes, which could guide subtype-targeted therapy. CMS4, also known as the mesenchymal subtype, has the greatest propensity to form distant metastases. CMS4 status and histopathological features of colorectal peritoneal carcinomatosis were investigated in this study...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29340767/analysis-of-prognostic-factors-after-resection-of-solitary-liver-metastasis-in-colorectal-cancer-a-22-year-bicentre-study
#13
Sara Acciuffi, Frank Meyer, Astrid Bauschke, Utz Settmacher, Hans Lippert, Roland Croner, Annelore Altendorf-Hofmann
PURPOSE: The investigation of the predictors of outcome after hepatic resection for solitary colorectal liver metastasis. METHODS: We recruited 350 patients with solitary colorectal liver metastasis at the University Hospitals of Jena and Magdeburg, who underwent curative liver resection between 1993 and 2014. All patients had follow-up until death or till summer 2016. RESULTS: The follow-up data concern 96.6% of observed patients. The 5- and 10-year overall survival rates were 47 and 28%, respectively...
January 16, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29340102/the-impact-of-antibiotic-usage-on-the-efficacy-of-chemoimmunotherapy-is-contingent-on-the-source-of-tumor-reactive-t-cells
#14
Michal P Kuczma, Zhi-Chun Ding, Tao Li, Tsadik Habtetsion, Tingting Chen, Zhonglin Hao, Locke Bryan, Nagendra Singh, James N Kochenderfer, Gang Zhou
In recent years the combined use of chemotherapy and immunotherapy, collectively termed chemoimmunotherapy, has emerged as a promising treatment option for patients with cancer. Antibiotics are commonly used to reduce infection-related complications in patients undergoing chemotherapy. Intriguingly, accumulating evidence has implicated gut microbiota as a critical determinant of host antitumor immune responses, raising the question as to whether the use of broad-spectrum antibiotics would invariably diminish tumor response to chemoimmunotherapies...
December 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29337962/the-relationship-between-right-sided-tumour-location-tumour-microenvironment-systemic-inflammation-adjuvant-therapy-and-survival-in-patients-undergoing-surgery-for-colon-and-rectal-cancer
#15
Meera Patel, Stephen T McSorley, James H Park, Campbell S D Roxburgh, Joann Edwards, Paul G Horgan, Donald C McMillan
BACKGROUND: There has been an increasing interest in the role of tumour location in the treatment and prognosis of patients with colorectal cancer (CRC), specifically in the adjuvant setting. Together with genomic data, this has led to the proposal that right-sided and left-sided tumours should be considered as distinct biological and clinical entities. The aim of the present study was to examine the relationship between tumour location, tumour microenvironment, systemic inflammatory response (SIR), adjuvant chemotherapy and survival in patients undergoing potentially curative surgery for stage I-III colon and rectal cancer...
January 16, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29337636/new-onset-cardiovascular-morbidity-in-older-adults-with-stage-i-to-iii-colorectal-cancer
#16
Kelly M Kenzik, Courtney Balentine, Joshua Richman, Meredith Kilgore, Smita Bhatia, Grant R Williams
Purpose We sought to determine the long-term risk of cardiovascular disease (CVD)-stroke and myocardial infarction-and congestive heart failure (CHF) in older patients with colorectal cancer, as well as to understand the roles that preexisting comorbidities and cancer therapy play in increasing this risk. Patients and Methods We evaluated individuals from the SEER-Medicare database with incident stage I to III colorectal cancer at age older than 65 years between January 1, 2000, and December 31, 2011 (n = 72,408) and compared these patients with a matched cohort of Medicare patients without cancer (n = 72,408)...
January 16, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29335393/peritoneal-metastases-of-colorectal-origin-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-hipec-the-financial-aspect
#17
Tomasz Jastrzębski, Marek Bębenek
The incidence of peritoneal carcinomatosis of colorectal cancer amounts to 5%-15% for synchronous metastases and as much as 40% in cases of local recurrence. Best results are obtained for cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This treatment offers much better outcomes, leading to 5-year survival rates of as much as 30%-50%. The procedures require significant experience in abdominal surgery, are time-consuming (mean duration of the procedure ranging from 6 to 8 hours) and are burdened by complications that are due not only to the procedure itself but also to the intraperitoneal administration of the cytostatic drug at elevated temperature (41...
December 30, 2017: Polski Przeglad Chirurgiczny
https://www.readbyqxmd.com/read/29333281/controversies-and-consensus-of-neoadjuvant-chemotherapy-in-soft-tissue-sarcomas
#18
Herbert H Loong, Kwan-Hung Wong, Teresa Tse
Together with surgery and radiotherapy, systemic treatment with cytotoxic chemotherapy and molecular targeted agents is one of the main therapeutic pillars in the treatment of soft-tissue sarcomas and is the mainstay of treatment in patients with advanced or metastatic disease. Unlike other more common malignancies such as breast and colorectal cancer, the role of chemotherapy when used in the adjuvant setting in soft-tissue sarcomas is less well defined. Results from prior studies have been conflicting, in part due to the heterogeneity and rarity of the disease, and large-scale meta-analysis has been performed to address this issue...
2018: ESMO Open
https://www.readbyqxmd.com/read/29333014/is-colorectal-cancer-in-young-40-years-different-from-those-in-the-elderly-40-years-experience-from-a-regional-care-center
#19
Rudresha A Haleshappa, Suparna Ajit Rao, Sunny Garg, C Lakshmaiah Kuntegowdanahalli, Govinda Babu Kanakasetty, Lokanatha Dasappa
Background: Colorectal cancer (CRC) is considered a disease of elderly. There has been a steady decrease in the incidence in those aged >50 years, with an alarming increase noted in adults aged <50 years. Subjects and Methods: We retrospectively analyzed 89 patients diagnosed with CRC aged <40 years between the years 2010 and 2014. Their clinical profile, treatment, and outcomes were studied. Results: The median age was 33 years with a male preponderance (56...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29332337/systemic-treatment-and-primary-tumor-location-in-patients-with-metastatic-colorectal-cancer
#20
Efstathios Antoniou, Nikolaos Andreatos, Georgios A Margonis, Apostolos Papalois, Jaeyun Wang, Christos Damaskos, Nikolaos Garmpis, Stefan Buettner, Amar Deshwar, Vasilios Pappas, Matthew J Weiss, Timothy M Pawlik, Emmanouel Pikoulis
PURPOSE: Tumor location (right-sided vs. left-sided) is known to exert a significant influence on the prognosis of primary colorectal cancer (CRC). Given the genetic continuity between primary and metastatic lesions, we aimed to summarize the existing literature on the prognostic implications of primary tumor site as well as to examine the response to chemotherapy by primary tumor location in patients with metastatic CRC (mCRC). METHODS: A structured review of the literature was performed between 6/1/2016-7/1/2016 using the Pubmed database...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
keyword
keyword
40932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"